Today: 29 April 2026
Browse Category

NASDAQ:RANI 17 October 2025 - 28 November 2025

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

RANI Stock Today, 28 November 2025: Price Action, Options Expiry and Outlook After the $1 Billion Chugai Deal

Rani Therapeutics shares traded around $1.59 on 28 November, down from the previous close of $1.62 but still well above pre-October levels. No new press releases or SEC filings were issued today. The stock’s recent surge followed a major Chugai Pharmaceutical collaboration and $60.3 million private placement. Market cap stands near $190–200 million with roughly 97.5 million shares outstanding.
28 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics shares surged over 300% in a month, jumping to $2.20–$2.50 after announcing a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal brought $10 million upfront and extended Rani’s cash runway into 2028 with a $60.3 million financing. Analyst targets rose as high as $11. Trading volume spiked tenfold, with the stock breaking key technical levels.
3 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Rani Therapeutics stock surged 330% in October, closing at $2.20 on Nov. 1 after announcing a $1.085 billion licensing deal with Chugai and positive preclinical data for its oral semaglutide pill. The company, which has no approved products or meaningful revenue, raised $60.3 million in a private placement. Analysts rate RANI a Buy, but warn of high risk due to ongoing losses and no product sales.
1 November 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Rani Therapeutics shares closed at $2.20 on Oct. 31, up 51.7% for the day, following a $1.09 billion collaboration deal with Chugai Pharma and a $60.3 million equity raise. Trading volume surged, with nearly 172 million shares changing hands Oct. 20. Founder Mir Imran bought 2.08 million shares Oct. 27. Wall Street analysts now rate RANI a “Strong Buy” with average price targets near $10–11.
31 October 2025
··
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics shares jumped 248% to close at $1.64 on October 17, 2025, after announcing a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in a private placement, boosting its cash position. Rani will get $10 million upfront from Chugai and up to $175 million in milestones for its first oral drug program.
20 October 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics (RANI) Stock Nearly Triples on $1B Chugai Deal – What Investors Should Know

Rani Therapeutics shares surged 248% to close at $1.64 on Oct. 17 after announcing a collaboration with Chugai Pharmaceutical worth up to $1.08 billion. The deal includes $10 million upfront and up to $175 million in milestones for the first drug. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. The company’s RaniPill technology delivers injectable drugs via oral capsules.
18 October 2025
···
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics shares surged nearly 190% to $1.37 on Oct. 17, 2025, after announcing a pharma partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal includes $10 million upfront, development and sales milestones, and potential royalties. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. Trading volume spiked to several times the daily average.
17 October 2025
···

Stock Market Today

  • Robinhood Markets Shares Dive 13% After Q1 Earnings Miss
    April 29, 2026, 5:55 PM EDT. Robinhood Markets shares fell 13.24% to $71.20 following its Q1 2026 earnings report, which missed revenue and earnings per share (EPS) estimates. Trading revenue rose 7% year-over-year to $623 million, but slower growth and a 47% decline in crypto trading revenue weighed on sentiment. Crypto trading, a key segment, suffered due to recent digital asset price declines. Robinhood's market cap stands at $74 billion, with trading volume surging 132% above average to 76.7 million shares. The company is focusing on real-world asset tokenization, an emerging blockchain use case recording ownership digitally, aiming to diversify revenue. Meanwhile, the broader market saw minimal moves: the S&P 500 slipped 0.04% and the Nasdaq inched up 0.04%. Peer Charles Schwab rose 0.36%, while Interactive Brokers dropped 0.57%, underscoring mixed investor reactions across financial services.

Latest article

Microsoft Stock Falls After Earnings Beat as Azure Growth Hits 40% and AI Revenue Surges

Microsoft Stock Falls After Earnings Beat as Azure Growth Hits 40% and AI Revenue Surges

29 April 2026
NEW YORK, April 29, 2026, 17:01 EDT Microsoft beat Wall Street’s fiscal third-quarter estimates on Wednesday as Azure revenue jumped 40% and its artificial-intelligence business crossed a $37 billion annual revenue run rate, but the stock slipped after hours as investors looked past the headline beat to the cost of the buildout. (Microsoft) The quarter matters because Microsoft has become one of the market’s cleanest tests of whether large technology companies can turn AI demand into durable cloud revenue. Azure, its cloud-computing platform, is the engine behind much of that bet, and the 40% growth rate came in as investors
Meta Stock Slides as $145 Billion AI Spending Plan Overshadows Blowout Earnings

Meta Stock Slides as $145 Billion AI Spending Plan Overshadows Blowout Earnings

29 April 2026
Meta Platforms shares dropped about 5% in after-hours trading Wednesday after the company raised its 2026 capital spending forecast to $125–$145 billion. First-quarter revenue rose 33% to $56.31 billion, beating estimates, while net income reached $26.77 billion, boosted by an $8.03 billion tax benefit. Meta expects second-quarter revenue of $58–$61 billion. Daily active users across its apps increased 4% to 3.56 billion.
Chipotle Stock Jumps After Chicken Bet Breaks Its Sales Slump

Chipotle Stock Jumps After Chicken Bet Breaks Its Sales Slump

29 April 2026
Chipotle Mexican Grill reported a 0.5% rise in first-quarter comparable sales, reversing recent declines and beating analyst expectations. Total revenue rose 7.4% to $3.09 billion, while shares jumped 7% in after-hours trading. Operating margin narrowed to 12.9% from 16.7% a year earlier. Menu items like Chicken al Pastor and Honey Chicken drove increased restaurant visits.
Go toTop